Biocon Limited

Societe Generale bought 6.5 lakh shares of Biocon Limited for ₹25.03 Cr at ₹385.00 apiece in a block deal.

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

French global investment bank with around EUR 1.6 trillion in assets. India FPI activity covers proprietary, market-making and client flows in listed Indian equities.